Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pantoprazole sodium products, etc. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding drugs, analgesics, and other fields. The company was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co., Ltd. in September 2021. Sailong Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Zhuhai, China.
Metrics to compare | 002898 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship002898PeersSector | |
---|---|---|---|---|
P/E Ratio | −64.9x | −10.7x | −0.5x | |
PEG Ratio | 0.12 | 0.03 | 0.00 | |
Price/Book | 4.7x | 3.3x | 2.6x | |
Price / LTM Sales | 9.4x | 4.0x | 3.2x | |
Upside (Analyst Target) | - | −5.3% | 41.4% | |
Fair Value Upside | Unlock | −7.6% | 6.0% | Unlock |